ASCO 2019: Highlights on results from the KEYNOTE 062 study

ASCO 2019

Speaker: Josep Tabernero

Reporting from ASCO 2019, J. Tabernero details the study results from the KEYNOTE-062 in advanced gastric or gastro-oesophageal junction adenocarcinoma that tested pembrolizumab vs chemotherapy vs their combination. Additional data analysis is ongoing to identify the populations who responded best to pembrolizumab.
Abstract discussed:
LBA4007: Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The phase III KEYNOTE-062 study, Josep
Tabernero